



Correction

Correction: Méroc et al. Systematic Literature Review of the Epidemiological Characteristics of Pneumococcal Disease Caused by the Additional Serotypes Covered by the 20-Valent Pneumococcal Conjugate Vaccine. *Microorganisms* 2023, 11, 1816

Estelle Méroc ¹, Mark A. Fletcher ², Germaine Hanquet ¹, Mary P. E. Slack ³, Marc Baay ¹, Kyla Hayford ⁴, Bradford D. Gessner ⁴ and Lindsay R. Grant ^{4,*}

¹ P95 Epidemiology & Pharmacovigilance, Koning Leopold III-laan 1, 3001 Leuven, Belgium; estelle.meroc@p-95.com (E.M.); germaine.hanquet@p-95.com (G.H.); marc.baay@p-95.com (M.B.)

² Emerging Markets Medical Affairs, Vaccines, Pfizer, 23–25 Av. du Dr Lannelongue, 75014 Paris, France; mark.a.fletcher@pfizer.com

³ School of Medicine & Dentistry, Griffith University Gold Coast Campus, Parklands Drive, Southport, QLD 4222, Australia; mary.slack@pfizer.com

⁴ Medical Development and Scientific Clinical Affairs, Pfizer Vaccines, 500 Arcola Road, Collegeville, PA 19426, USA; kyla.hayford@pfizer.com (K.H.); bradford.gessner@pfizer.com (B.D.G.)

* Correspondence: lindsay.grant@pfizer.com; Tel.: +1-(443)-447-2513

In the original publication [1], there was a mistake in Table S5 (adults), which was a duplicate of Table S5 (children). The corrected Table S5 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Table S5. Meta-analysis of serotype-specific proportion * of IPD isolates from children and adults.

Children	Serotype	N (Studies)	Proportion (95% CI)
PCV13 NIP, initial period (<3 years)			
	All PCV13	26	50.3 (41.3–59.3)
	PCV20nonPCV13		
	8	22	2.1 (1.3–3.3)
	10A	24	3.5 (2.8–4.4)
	11A	20	1.9 (1.3–2.9)
	12F	24	4.4 (2.6–7.6)
	15B/C	31	7.2 (5.6–9.1)
	22F	25	3.6 (2.5–5.3)
	33F	23	3.2 (2.3–4.6)
PCV13 NIP, later period (≥3 years)			
	All PCV13	17	44.5 (30.6–59.3)
	PCV20nonPCV13		
	8	19	3.8 (2.5–5.8)
	10A	18	5.9 (4.5–7.7)
	11A	15	1.9 (1.6–2.3)
	12F	20	4.9 (3.2–7.4)
	15B/C	18	6.2 (4.4–8.7)
	22F	20	4.2 (2.7–6.3)
	33F	18	4.4 (3.0–6.4)



Received: 5 September 2024

Accepted: 15 November 2024

Published: 31 March 2025

Citation: Méroc, E.; Fletcher, M.A.; Hanquet, G.; Slack, M.P.E.; Baay, M.; Hayford, K.; Gessner, B.D.; Grant, L.R.

Correction: Méroc et al. Systematic Literature Review of the Epidemiological Characteristics of Pneumococcal Disease Caused by the Additional Serotypes Covered by the 20-Valent Pneumococcal Conjugate Vaccine. *Microorganisms* 2023, 11, 1816. *Microorganisms* 2025, 13, 793.

<https://doi.org/10.3390/microorganisms13040793>

Copyright: © 2025 by the authors.

Licensee MDPI, Basel, Switzerland.

This article is an open access article

distributed under the terms and

conditions of the Creative Commons

Attribution (CC BY) license

(<https://creativecommons.org/licenses/by/4.0/>).

Table S5. Cont.

Adults	Serotype	N (Studies)	Proportion (95% CI)
PCV13 NIP, initial period (<3 years)			
	All PCV13	13	49.5 (45.0–57.0)
	PCV20nonPCV13		
	8	10	4.1 (1.6–10.4)
	10A	8	1.8 (1.0–3.5)
	11A	10	3.7 (2.4–5.6)
	12F	7	2.4 (1.5–4.0)
	15B/C	11	2.5 (1.7–3.6)
	22F	13	7.7 (5.9–9.9)
	33F	7	1.8 (1.2–2.7)
PCV13 NIP, later period (≥ 3 years)			
	All PCV13	9	27.3 (19.6–36.7)
	PCV20nonPCV13		
	8	13	10.2 (7.6–13.4)
	10A	13	2.4 (1.9–3.0)
	11A	13	2.7 (2.4–3.1)
	12F	13	6.2 (4.7–8.1)
	15B/C	11	1.5 (1.2–2.0)
	22F	13	6.7 (5.7–7.8)
	33F	12	2.5 (1.8–3.4)

* Calculated with a binomial random-effects meta-analytic model for each serotype-specific proportion independently. Consequently, the sum of all PCV20nonPCV13 serotypes may exceed 100%.

Reference

1. Méroc, E.; Fletcher, M.A.; Hanquet, G.; Slack, M.P.E.; Baay, M.; Hayford, K.; Gessner, B.D.; Grant, L.R. Systematic Literature Review of the Epidemiological Characteristics of Pneumococcal Disease Caused by the Additional Serotypes Covered by the 20-Valent Pneumococcal Conjugate Vaccine. *Microorganisms* **2023**, *11*, 1816. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.